1.	The use of specific drugs to prevent, treat, or diagnose a disease is known as:
A)	toxicology.
B)	pharmacokinetics.
C)	pharmacotherapeutics.
D)	toxicokinetics.
E)	dynamic equilibrium.

2.	The study of how the body deals with a drug in terms of the way the drug is absorbed, distributed, and eliminated is known as:
A)	toxicology.
B)	pharmacodynamics.
C)	pharmacy.
D)	pharmacokinetic.
E)	biodynamics.

3.	Toxicology is:
A)	the study of the harmful effects of chemicals.
B)	the study of a drug's beneficial effects.
C)	the analysis of drug absorption, distribution, and metabolism.
D)	the preparation and dispensing of therapeutic medications.
E)	the analysis of a drug's molecular structure.

4.	The generic name of a drug:
A)	is also known as the “official” or “nonproprietary” name.
B)	is often derived from the chemical name.
C)	tends to be somewhat shorter than the drug's chemical name.
D)	all of the above
E)	none of the above

5.	If there is no existing patent for a drug, or if the patent has expired, the same drug may be marketed by separate drug companies under different:
A)	chemical names.
B)	generic names.
C)	trade name.s
D)	nonproprietary names.
E)	organic names.

6.	The generic form of a drug is considered as safe and effective as the original, brand-name product if the generic form _________ as the brand-name drug.
A)	has the same type and amount of active ingredient(s)
B)	uses the same administration route
C)	has the same pharmacokinetic profile (drug absorption, plasma levels, and so forth)
D)	produces the same therapeutic effects
E)	all the above

7.	During drug testing and approval, the drug is usually tested in a relatively small sample (200 to 300 people) with a specific disease or pathologic condition during:
A)	preclinical trials.
B)	phase 1 clinical trials.
C)	phase 2 clinical trials.
D)	postmarketing surveillance.
E)	none of the above

8.	Drugs that can be purchased directly by the consumer without a prescription are also known as:
A)	nonproprietary medications.
B)	schedule I controlled substances.
C)	schedule II controlled substances.
D)	schedule III controlled substances.
E)	over-the-counter drugs.

9.	The point at which there is no further increase in response to a drug, even if the dosage continues to be increased is known as the drug's:
A)	ceiling effect.
B)	maximal efficacy.
C)	potency.
D)	all of the above
E)	A and B only

10.	When two drugs are compared, the drug that requires a lower dose to produce the same effect as a higher dose of the second drug is said to:
A)	be more potent.
B)	be impotent.
C)	have a greater maximal efficacy.
D)	have a greater therapeutic index.
E)	be pharmacosuperior.

11.	When evaluating drug safety, the dose that causes 50 percent of subjects to exhibit a specific adverse effect is known as the:
A)	median therapeutic dose.
B)	median toxic dose.
C)	therapeutic index.
D)	ceiling effect.
E)	threshold dose.

12.	In general, the greater the value of the _______, the safer the drug is considered to be.
A)	median effective dose
B)	threshold dose
C)	therapeutic index (TI)
D)	ceiling effect
E)	potency index

Answer Key

1.	C
2.	D
3.	A
4.	D
5.	C
6.	E
7.	C
8.	E
9.	E
10.	A
11.	B
12.	C